1. Insights from a Pan India Sero-Epidemiological survey (Phenome-India Cohort) for SARS-CoV2.
- Author
-
Naushin S, Sardana V, Ujjainiya R, Bhatheja N, Kutum R, Bhaskar AK, Pradhan S, Prakash S, Khan R, Rawat BS, Tallapaka KB, Anumalla M, Chandak GR, Lahiri A, Kar S, Mulay SR, Mugale MN, Srivastava M, Khan S, Srivastava A, Tomar B, Veerapandian M, Venkatachalam G, Vijayakumar SR, Agarwal A, Gupta D, Halami PM, Peddha MS, Sundaram GM, Veeranna RP, Pal A, Agarwal VK, Maurya AK, Singh RK, Raman AK, Anandasadagopan SK, Karuppanan P, Venkatesan S, Sardana HK, Kothari A, Jain R, Thakur A, Parihar DS, Saifi A, Kaur J, Kumar V, Mishra A, Gogeri I, Rayasam G, Singh P, Chakraborty R, Chaturvedi G, Karunakar P, Yadav R, Singhmar S, Singh D, Sarkar S, Bhattacharya P, Acharya S, Singh V, Verma S, Soni D, Seth S, Vashisht S, Thakran S, Fatima F, Singh AP, Sharma A, Sharma B, Subramanian M, Padwad YS, Hallan V, Patial V, Singh D, Tripude NV, Chakrabarti P, Maity SK, Ganguly D, Sarkar J, Ramakrishna S, Kumar BN, Kumar KA, Gandhi SG, Jamwal PS, Chouhan R, Jamwal VL, Kapoor N, Ghosh D, Thakkar G, Subudhi U, Sen P, Chaudhury SR, Kumar R, Gupta P, Tuli A, Sharma D, Ringe RP, D A, Kulkarni M, Shanmugam D, Dharne MS, Dastager SG, Joshi R, Patil AP, Mahajan SN, Khan AH, Wagh V, Yadav RK, Khilari A, Bhadange M, Chaurasiya AH, Kulsange SE, Khairnar K, Paranjape S, Kalita J, Sastry NG, Phukan T, Manna P, Romi W, Bharali P, Ozah D, Sahu RK, Babu EV, Sukumaran R, Nair AR, Valappil PK, Puthiyamadam A, Velayudhanpillai A, Chodankar K, Damare S, Madhavi Y, Aggarwal VV, Dahiya S, Agrawal A, Dash D, and Sengupta S
- Subjects
- Biomarkers blood, COVID-19 diagnosis, COVID-19 immunology, COVID-19 virology, Female, Host-Pathogen Interactions, Humans, Immunity, Humoral, India epidemiology, Longitudinal Studies, Male, Predictive Value of Tests, Risk Assessment, Risk Factors, Seroepidemiologic Studies, Time Factors, Antibodies, Neutralizing blood, Antibodies, Viral blood, COVID-19 epidemiology, COVID-19 Serological Testing, SARS-CoV-2 immunology
- Abstract
To understand the spread of SARS-CoV2, in August and September 2020, the Council of Scientific and Industrial Research (India) conducted a serosurvey across its constituent laboratories and centers across India. Of 10,427 volunteers, 1058 (10.14%) tested positive for SARS-CoV2 anti-nucleocapsid (anti-NC) antibodies, 95% of which had surrogate neutralization activity. Three-fourth of these recalled no symptoms. Repeat serology tests at 3 (n = 607) and 6 (n = 175) months showed stable anti-NC antibodies but declining neutralization activity. Local seropositivity was higher in densely populated cities and was inversely correlated with a 30-day change in regional test positivity rates (TPRs). Regional seropositivity above 10% was associated with declining TPR. Personal factors associated with higher odds of seropositivity were high-exposure work (odds ratio, 95% confidence interval, p value: 2.23, 1.92-2.59, <0.0001), use of public transport (1.79, 1.43-2.24, <0.0001), not smoking (1.52, 1.16-1.99, 0.0257), non-vegetarian diet (1.67, 1.41-1.99, <0.0001), and B blood group (1.36, 1.15-1.61, 0.001)., Competing Interests: SN, VS, RU, NB, RK, AB, SP, SP, RK, BR, KT, MA, GC, AL, SK, SM, MM, MS, SK, AS, BT, MV, GV, SV, AA, DG, PH, MP, GS, RV, AP, VA, AM, RS, AR, SA, PK, SV, HS, AK, RJ, AT, DP, AS, JK, VK, AM, IG, GR, PS, RC, GC, PK, RY, SS, DS, SS, PB, SA, VS, SV, DS, SS, SV, ST, FF, AS, AS, BS, MS, YP, VH, VP, DS, NT, PC, SM, DG, JS, SR, BK, KK, SG, PJ, RC, VJ, NK, DG, GT, US, PS, SC, RK, PG, AT, DS, RR, AD, MK, DS, MD, SD, RJ, AP, SM, AK, VW, RY, AK, MB, AC, SK, KK, SP, JK, NS, TP, PM, WR, PB, DO, RS, EB, RS, AN, PV, AP, AV, KC, SD, YM, VA, SD, AA, DD, SS No competing interests declared, (© 2021, Naushin et al.)
- Published
- 2021
- Full Text
- View/download PDF